Market breadth in biotech supports a constructive FBIO stock forecast, particularly with fund flows pointing to increased institutional exposure in niche pharmaceutical innovators. BAY HARBOR ISLAND, Fla. (AP) — BAY HARBOR ISLAND, Fla. (AP) — Fortress Biotech Inc. (FBIO) on Tuesday reported a loss of $5 million in its third quarter. Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time. Based on Q2 performance, FBIO stock forecast models adjusted EBITDA improvement by 8–10% year-over-year if R&D expenditure stays under the projected $70M cap.
